Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2013

Open Access 01-12-2013 | Research

EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth

Authors: Agnieszka Martowicz, Johannes Rainer, Julien Lelong, Gilbert Spizzo, Guenther Gastl, Gerold Untergasser

Published in: Molecular Cancer | Issue 1/2013

Login to get access

Abstract

Introduction

The Epithelial Cell Adhesion Molecule (EpCAM) has been shown to be strongly expressed in human breast cancer and cancer stem cells and its overexpression has been supposed to support tumor progression and metastasis. However, effects of EpCAM overexpression on normal breast epithelial cells have never been studied before. Therefore, we analyzed effects of transient adenoviral overexpression of EpCAM on proliferation, migration and differentiation of primary human mammary epithelial cells (HMECs).

Methods

HMECs were transfected by an adenoviral system for transient overexpression of EpCAM. Thereafter, changes in cell proliferation and migration were studied using a real time measurement system. Target gene expression was evaluated by transcriptome analysis in proliferating and polarized HMEC cultures. A Chicken Chorioallantoic Membrane (CAM) xenograft model was used to study effects on in vivo growth of HMECs.

Results

EpCAM overexpression in HMECs did not significantly alter gene expression profile of proliferating or growth arrested cells. Proliferating HMECs displayed predominantly glycosylated EpCAM isoforms and were inhibited in cell proliferation and migration by upregulation of p27KIP1 and p53. HMECs with overexpression of EpCAM showed a down regulation of E-cadherin. Moreover, cells were more resistant to TGF-β1 induced growth arrest and maintained longer capacities to proliferate in vitro. EpCAM overexpressing HMECs xenografts in chicken embryos showed hyperplastic growth, lack of lumen formation and increased infiltrates of the chicken leukocytes.

Conclusions

EpCAM revealed oncogenic features in normal human breast cells by inducing resistance to TGF-β1-mediated growth arrest and supporting a cell phenotype with longer proliferative capacities in vitro. EpCAM overexpression resulted in hyperplastic growth in vivo. Thus, we suggest that EpCAM acts as a prosurvival factor counteracting terminal differentiation processes in normal mammary glands.
Appendix
Available only for authorised users
Literature
1.
Litvinov SV, Bakker HA, Gourevitch MM, Velders MP, Warnaar SO: Evidence for a role of the epithelial glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion. Cell Adhes Commun. 1994, 2: 417-428. 10.3109/15419069409004452CrossRefPubMed
2.
Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO: Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol. 1994, 125: 437-446. 10.1083/jcb.125.2.437CrossRefPubMed
3.
Anderson R, Schaible K, Heasman J, Wylie C: Expression of the homophilic adhesion molecule, Ep-CAM, in the mammalian germ line. J Reprod Fertil. 1999, 116: 379-384. 10.1530/jrf.0.1160379CrossRefPubMed
4.
Lu TY, Lu RM, Liao MY, Yu J, Chung CH, Kao CF: Epithelial cell adhesion molecule regulation is associated with the maintenance of the undifferentiated phenotype of human embryonic stem cells. J Biol Chem. 2010, 285: 8719-8732. 10.1074/jbc.M109.077081PubMedCentralCrossRefPubMed
5.
van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG: EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis. 2010, 31: 1913-1921. 10.1093/carcin/bgq187CrossRefPubMed
6.
Slanchev K, Carney TJ, Stemmler MP, Koschorz B, Amsterdam A, Schwarz H: The epithelial cell adhesion molecule EpCAM is required for epithelial morphogenesis and integrity during zebrafish epiboly and skin development. PLoS Genet. 2009, 5: e1000563- 10.1371/journal.pgen.1000563PubMedCentralCrossRefPubMed
7.
Nagao K, Zhu J, Heneghan MB, Hanson JC, Morasso MI, Tessarollo L: Abnormal placental development and early embryonic lethality in EpCAM-null mice. PLoS One. 2009, 4: e8543- 10.1371/journal.pone.0008543PubMedCentralCrossRefPubMed
8.
Kempers MJ, Kuiper RP, Ockeloen CW, Chappuis PO, Hutter P, Rahner N: Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol. 2011, 12: 49-55. 10.1016/S1470-2045(10)70265-5PubMedCentralCrossRefPubMed
9.
Basak S, Speicher D, Eck S, Wunner W, Maul G, Simmons MS: Colorectal carcinoma invasion inhibition by CO17-1A/GA733 antigen and its murine homologue. J Natl Cancer Inst. 1998, 90: 691-697. 10.1093/jnci/90.9.691CrossRefPubMed
10.
Winter MJ, Nagelkerken B, Mertens AE, Rees-Bakker HA, Briaire-de Bruijn IH, Litvinov SV: Expression of Ep-CAM shifts the state of cadherin-mediated adhesions from strong to weak. Exp Cell Res. 2003, 285: 50-58. 10.1016/S0014-4827(02)00045-9CrossRefPubMed
11.
Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M: Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol. 2009, 11: 162-171. 10.1038/ncb1824CrossRefPubMed
12.
Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L: An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol. 2010, 21: 275-282. 10.1093/annonc/mdp314CrossRefPubMed
13.
Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G: Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet. 2000, 356: 1981-1982. 10.1016/S0140-6736(00)03312-2CrossRefPubMed
14.
Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H: High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat. 2004, 86: 207-213. 10.1023/B:BREA.0000036787.59816.01CrossRefPubMed
15.
Schmidt M, Ruttinger D, Sebastian M, Hanusch CA, Marschner N, Baeuerle PA: Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer. Ann Oncol. 2012, 9: 2306-2313.CrossRef
16.
Bokemeyer C: Catumaxomab–trifunctional anti-EpCAM antibody used to treat malignant ascites. Expert Opin Biol Ther. 2010, 10: 1259-1269. 10.1517/14712598.2010.504706CrossRefPubMed
17.
Balzar M, Winter MJ, de Boer CJ, Litvinov SV: The biology of the 17-1A antigen (Ep-CAM). J Mol Med (Berl). 1999, 77: 699-712. 10.1007/s001099900038.CrossRef
18.
Martowicz A, Spizzo G, Gastl G, Untergasser G: Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines. BMC Cancer. 2012, 12: 501- 10.1186/1471-2407-12-501PubMedCentralCrossRefPubMed
19.
Untergasser G, Steurer M, Zimmermann M, Hermann M, Kern J, Amberger A: The Dickkopf-homolog 3 is expressed in tumor endothelial cells and supports capillary formation. Int J Cancer. 2008, 122: 1539-1547.CrossRefPubMed
20.
21.
Rainer J, Lelong J, Bindreither D, Mantinger C, Ploner C, Geley S: Research resource: transcriptional response to glucocorticoids in childhood acute lymphoblastic leukemia. Mol Endocrinol. 2012, 26: 178-193. 10.1210/me.2011-1213CrossRefPubMed
22.
Chen HF, Chuang CY, Lee WC, Huang HP, Wu HC, Ho HN: Surface marker epithelial cell adhesion molecule and E-cadherin facilitate the identification and selection of induced pluripotent stem cells. Stem Cell Rev. 2011, 7: 722-735. 10.1007/s12015-011-9233-yCrossRefPubMed
23.
Gonzalez B, Denzel S, Mack B, Conrad M, Gires O: EpCAM is involved in maintenance of the murine embryonic stem cell phenotype. Stem Cells. 2009, 27: 1782-1791. 10.1002/stem.97CrossRefPubMed
24.
Sarrio D, Franklin CK, Mackay A, Reis-Filho JS, Isacke CM: Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells. 2012, 30: 292-303. 10.1002/stem.791CrossRefPubMed
25.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003, 100: 3983-3988. 10.1073/pnas.0530291100PubMedCentralCrossRefPubMed
26.
Munz M, Baeuerle PA, Gires O: The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res. 2009, 69: 5627-5629. 10.1158/0008-5472.CAN-09-0654CrossRefPubMed
27.
Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA: EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 2004, 64: 5818-5824. 10.1158/0008-5472.CAN-04-0754CrossRefPubMed
28.
Schmelzer E, Reid LM: EpCAM expression in normal, non-pathological tissues. Front Biosci. 2008, 13: 3096-3100. 10.2741/2911CrossRefPubMed
29.
Carpenter G, Red BM: EpCAM: another surface-to-nucleus missile. Cancer Cell. 2009, 15: 165-166. 10.1016/j.ccr.2009.02.005CrossRefPubMed
30.
Munz M, Fellinger K, Hofmann T, Schmitt B, Gires O: Glycosylation is crucial for stability of tumour and cancer stem cell antigen EpCAM. Front Biosci. 2008, 13: 5195-5201.CrossRefPubMed
31.
Winter MJ, Cirulli V, Briaire-de Bruijn IH, Litvinov SV: Cadherins are regulated by Ep-CAM via phosphaditylinositol-3 kinase. Mol Cell Biochem. 2007, 302: 19-26. 10.1007/s11010-007-9420-yCrossRefPubMed
32.
Garbe JC, Holst CR, Bassett E, Tlsty T, Stampfer MR: Inactivation of p53 function in cultured human mammary epithelial cells turns the telomere-length dependent senescence barrier from agonescence into crisis. Cell Cycle. 2007, 6: 1927-1936. 10.4161/cc.6.15.4519CrossRefPubMed
33.
Garbe JC, Bhattacharya S, Merchant B, Bassett E, Swisshelm K, Feiler HS: Molecular distinctions between stasis and telomere attrition senescence barriers shown by long-term culture of normal human mammary epithelial cells. Cancer Res. 2009, 69: 7557-7568. 10.1158/0008-5472.CAN-09-0270PubMedCentralCrossRefPubMed
34.
35.
Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW: Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997, 88: 593-602. 10.1016/S0092-8674(00)81902-9CrossRefPubMed
36.
Stampfer MR, Garbe J, Levine G, Lichtsteiner S, Vasserot AP, Yaswen P: Expression of the telomerase catalytic subunit, hTERT, induces resistance to transforming growth factor beta growth inhibition in p16INK4A(-) human mammary epithelial cells. Proc Natl Acad Sci USA. 2001, 98: 4498-4503. 10.1073/pnas.071483998PubMedCentralCrossRefPubMed
37.
Sankpal NV, Willman MW, Fleming TP, Mayfield JD, Gillanders WE: Transcriptional repression of epithelial cell adhesion molecule contributes to p53 control of breast cancer invasion. Cancer Res. 2009, 69: 753-757. 10.1158/0008-5472.CAN-08-2708PubMedCentralCrossRefPubMed
38.
Boehme KA, Blattner C: Regulation of p53–insights into a complex process. Crit Rev Biochem Mol Biol. 2009, 44: 367-392. 10.3109/10409230903401507CrossRefPubMed
39.
Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM: p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev. 2004, 18: 862-876. 10.1101/gad.1185504PubMedCentralCrossRefPubMed
40.
Chaves-Perez A, Mack B, Maetzel D, Kremling H, Eggert C, Harreus U: EpCAM regulates cell cycle progression via control of cyclin D1 expression. Oncogene. 2013, 32: 641-650. 10.1038/onc.2012.75CrossRefPubMed
41.
Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O: The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene. 2004, 23: 5748-5758. 10.1038/sj.onc.1207610CrossRefPubMed
42.
Kuhn S, Koch M, Nubel T, Ladwein M, Antolovic D, Klingbeil P: A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res. 2007, 5: 553-567. 10.1158/1541-7786.MCR-06-0384CrossRefPubMed
43.
Maghzal N, Vogt E, Reintsch W, Fraser JS, Fagotto F: The tumor-associated EpCAM regulates morphogenetic movements through intracellular signaling. J Cell Biol. 2010, 191: 645-659. 10.1083/jcb.201004074PubMedCentralCrossRefPubMed
44.
Untergasser G, Koch HB, Menssen A, Hermeking H: Characterization of epithelial senescence by serial analysis of gene expression: identification of genes potentially involved in prostate cancer. Cancer Res. 2002, 62: 6255-6262.PubMed
45.
Untergasser G, Gander R, Rumpold H, Heinrich E, Plas E, Berger P: TGF-beta cytokines increase senescence-associated beta-galactosidase activity in human prostate basal cells by supporting differentiation processes, but not cellular senescence. Exp Gerontol. 2003, 38: 1179-1188. 10.1016/j.exger.2003.08.008CrossRefPubMed
46.
47.
Gaiser MR, Lammermann T, Feng X, Igyarto BZ, Kaplan DH, Tessarollo L: Cancer-associated epithelial cell adhesion molecule (EpCAM; CD326) enables epidermal Langerhans cell motility and migration in vivo. Proc Natl Acad Sci USA. 2012, 109: E889-E897. 10.1073/pnas.1117674109PubMedCentralCrossRefPubMed
Metadata
Title
EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth
Authors
Agnieszka Martowicz
Johannes Rainer
Julien Lelong
Gilbert Spizzo
Guenther Gastl
Gerold Untergasser
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2013
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-12-56

Other articles of this Issue 1/2013

Molecular Cancer 1/2013 Go to the issue

Research

PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling

Research

Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells

Research

miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer

Research

MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1

Short communication

Gene expression profiling of chronic myeloid leukemia with variant t(9;22) reveals a different signature from cases with classic translocation

Research

The identification of novel targets of miR-16 and characterization of their biological functions in cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits